8 d. ago Novo Nordisk faces fierce competition in China’s diabetes drug market

Competition in the mainland Chinese market for diabetes and weight loss drugs is set to intensify as more than 60 late-stage drug candidates are undergoing clinical trials, according to a recent report. Up to 20 biosimilar or generic copies will vie for market share and add pricing pressure after Denmark-based Novo Nordisk’s semaglutide product loses patent protection in China next year, according to Boston-based global consultancy L.E.K. Consulting. Novo Nordisk’s patent will expire in 2031 in...

Events

1 week ago Merck seeks China and US approval of TGCT drug after Phase III success

Merck seeks China and US approval of TGCT drug after Phase III success  Pharmaceutical Technology

Events

2 w. ago Cancer drug trials in China’s Hainan, world’s fastest coilgun: 5 weekend reads

Cancer drug trials in China’s Hainan, world’s fastest coilgun: 5 weekend reads  South China Morning Post

Events

2 w. ago Chinese biotech firm secures Pfizer deal despite trade tensions

Chinese drug maker 3SBio has licensed its new cancer drug to US pharmaceutical giant Pfizer in the largest deal ever for China’s biotech industry, underscoring the strong commercial Sino-US ties despite geopolitical headwinds. Based in Shenyang, capital of northeastern Liaoning province, 3SBio will receive a US$1.25 billion upfront payment for licensing its cancer drug SSGJ-707 exclusively to Pfizer, which will manufacture and commercialise the drug outside mainland China, the companies...

Economics

2 w. ago Pfizer Inks Up to $6B Deal to Market 3SBio's Cancer Drug Outside China

Pfizer Inks Up to $6B Deal to Market 3SBio's Cancer Drug Outside China  Investopedia

Economics

3 w. ago Pfizer in deal with China's 3SBio to license cancer drug candidate, take equity stake

Pfizer in deal with China's 3SBio to license cancer drug candidate, take equity stake  Reuters

Events

3 w. ago Pfizer signs licensing deal worth about $6 billion with China's 3SBio for cancer drug

Pfizer signs licensing deal worth about $6 billion with China's 3SBio for cancer drug  Reuters

Economics

3 w. ago Pfizer signs up to $6 billion licensing deal with China's 3SBio for cancer drug

Pfizer signs up to $6 billion licensing deal with China's 3SBio for cancer drug  Reuters

Economics

3 w. ago ‘China’s Ozempic’ may vie with Eli Lilly, Novo Nordisk for global weight

Drug manufacturers to focus on China and Japan, where penetration is low and innovation continues to emerge, Morgan Stanley says.

Politics

3 w. ago Why Trump’s drug price promise may fail to protect China’s pharma industry

Why Trump’s drug price promise may fail to protect China’s pharma industry  South China Morning Post

Events

4 w. ago Trump Live Updates: China Tariff Pause, Drug Prices and More

Trump Live Updates: China Tariff Pause, Drug Prices and More  The New York Times

Politics

4 w. ago Trump administration live updates: U.S. and China agree to pause tariffs; president signs executive order on drug pricing

Trump administration live updates: U.S. and China agree to pause tariffs; president signs executive order on drug pricing  NBC News

Politics

4 w. ago Trump administration live updates: U.S. and China agree to pause tariffs; president to sign executive order on drug pricing

Trump administration live updates: U.S. and China agree to pause tariffs; president to sign executive order on drug pricing  NBC News

Politics

4 w. ago Trump administration live updates: U.S. and China agree to pause tariffs; president to sign drug prices executive order

Trump administration live updates: U.S. and China agree to pause tariffs; president to sign drug prices executive order  NBC News

Politics